Texas salon owner rebuilds after deadly floods destroy 2-week-old business
Nelson's Vintage Hair Co., which opened on June 21, was among the countless properties damaged when unprecedented flooding struck Kerr County on July 4, claiming at least 95 lives and leaving more than 170 people missing.
"The community itself is still in shock. I know I am," Nelson told ABC News. "This is overwhelming. Nothing like this have I ever seen living here."
Despite losing her business, Nelson immediately stepped up to help her community. A former member of the Ingraham Volunteer Fire Department, she returned to assist with emergency response efforts.
"When I woke up Friday morning and couldn't get to my business, my reaction was to call and say, 'What do you need me to do?'" Nelson explained. "Staying busy has helped me get through this."
MORE: 'I needed to get to my boys': Mother recounts Texas camp flood rescue
As the community begins to recover, Nelson faces difficult decisions about rebuilding. While her landlord is already working to restore the building, removing mud and bleaching the structure down to its studs, questions remain about insurance coverage and future flood risks.
"I fully intend on staying with my landlord," Nelson said. "But there are some concerns about whether insurance will cover us again, and whether this could ever happen again in my lifetime."
The devastating floods have sparked discussions about improving the region's flood warning systems. The Texas Legislature is now considering this issue as part of an upcoming special session, with Gov. Greg Abbott including flood-related measures among his priority agenda items.
MORE: Texas flood: Kickoff meeting for Kerr County warning system project had been planned for mid-July
When asked about the warning system debate, Nelson remained thoughtful.
"I think a flood warning system would be a good choice," she said, adding, "Moving forward, there will be measures, one way or another, to protect our community."
The flooding, which dumped as much as 15 inches of rain in some areas, has become one of the deadliest natural disasters in recent Texas history, particularly impacting Kerr County, where 36 children were among those who lost their lives.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
38 minutes ago
- Yahoo
BirdieBox Reemerges Under New Ownership: A Stronger, More Purposeful Future Begins
IRVING, Texas, July 23, 2025--(BUSINESS WIRE)--BirdieBox, the premium provider of curated corporate gifting solutions, is proud to announce its revitalization under new ownership and leadership - marking a bold new chapter centered on operational integrity, elevated client service, and sustainable growth. Previously, BirdieBox experienced instability and organizational strain that impacted customers, vendors and employees. Recognizing the strength of the brand and the loyalty of its client base, an existing institutional investor has taken active ownership and is leading the company forward with renewed clarity, capital, and commitment. "We're not starting over - we're starting stronger," said Spring Hollis, CEO of Star Strong Capital and interim CEO of BirdieBox. "We believe in this brand's mission, its people, and its potential. Our team has the expertise and appetite for the challenge that turnarounds demand. BirdieBox has a great product - it simply lacked the stewardship to deliver with excellence. That changes now." As part of this transformation, BirdieBox now operates under BirdieBox Holdings, headquartered in Irving, Texas. The company has made key leadership and operational staffing changes to support a more stable and high-performing future, while re-investing in its most experienced and client-loved team members with a renewed commitment to delivering exceptional gifting experiences. BirdieBox has also engaged co-founder and former Chief Strategy Officer behind their most successful years, Michael Myers, to help shape the next chapter, ensuring the core spirit of BirdieBox continues to drive its growth. "BirdieBox was a special place… built on a foundation of client trust and an unwavering quest to craft the perfect user experience," Myers emphasizes. "Somewhere along the way, those things became secondary. It's time to return to the principles of transparency, integrity and execution that once had this company on a fast track to greatness… and this is the leadership team to do just that." With new investment and leadership, BirdieBox is rebuilding with intention - enhancing fulfillment systems, stabilizing timelines, and improving project delivery across every touchpoint. Clients will still enjoy the company's signature white-glove service - branded pop-ups, custom portals, and thoughtfully curated gifting campaigns - now with a foundation built for reliability and excellence. "This is more than a relaunch," Hollis added. "To the clients who've stuck with us, and to the ones giving us a fresh look, we're here to demonstrate the enduring value of personalized gifting experiences." For more information, visit For details about the transition, visit View source version on Contacts For media inquiries, contact Rebecca Louzan at rebecca@ or (781) 635-6719 Sign in to access your portfolio
Forbes
40 minutes ago
- Forbes
InnovationRx: Sarepta Blinks In Showdown With FDA
In this week's edition of InnovationRx, we look at Sarepta's showdown with the FDA, Moderna's use of quantum computers, a new top drug regulator at the FDA, ARCH Venture's latest biotech company, and more. To get it in your inbox, subscribe here . Sarepta Therapeutics CEO Douglas Ingram Bloomberg Finance U sually when the FDA asks a drugmaker to halt distribution of a treatment, the company complies. Last week, in a remarkable showdown, Sarepta Therapeutics refused to stop distribution of Elevidys, its therapy for the muscle-wasting disease Duchenne muscular dystrophy as the FDA had requested. Then, in a remarkable reversal, on Monday Sarepta blinked and said that it would indeed pause all shipments of Elevidys by Tuesday evening. The latest twist in the saga followed a decision by Children's Hospital Los Angeles to halt use of the drug while it was facing regulatory uncertainty. Elevidys is a gene therapy for Duchenne, a particularly severe form of muscular dystrophy, which typically kills patients before they turn 30. The one-time intravenous infusion was first approved in 2023 in an unusual decision that was made unilaterally by Peter Marks, a top FDA official, despite misgivings of his staff. Last Friday evening, the FDA had requested that Cambridge, Mass.-based Sarepta voluntarily stop all shipments of the drug, citing the deaths of three patients who had taken Elevidys or a similar drug (that's in early-stage clinical trials) from liver failure. Later that evening, Sarepta responded that it would continue to ship Elevidys for patients who do not use wheelchairs (who are generally younger and healthier), citing its own analysis that there were no new safety problems in these patients. It had already voluntarily halted sales to patients who use wheelchairs. The face-off between Sarepta and the FDA comes at a time when investment in gene therapy has slowed, and as Sarepta itself has laid off hundreds of employees. Sarepta's stock is down nearly 40% since last Thursday's close. It's unclear how long the 'pause' might last. The company is working on an enhanced immune-suppressing protocol that could reduce liver toxicity, but a senior FDA official told Stat yesterday that the drug faces an 'arduous and treacherous path' back to the market. Whatever ultimately happens, the ongoing saga highlights the questions about what risks are acceptable for patients with diseases that are fatal at a young age and how the potential for treatment should be balanced against the possibility of death from the therapy itself. Moderna M essenger RNA (or mRNA) is a hugely promising technology for future vaccines and therapies, as was demonstrated during the COVID-19 pandemic. One of its major advantages is that it provides instructions for the body itself to manufacture the medicine it needs, rather than delivering it. But developing new treatments is challenging, Wade Davis, vice president of computational science at Moderna (best known for developing those COVID vaccines), told Forbes . That's in part because of the fragile nature of mRNA–its primary function is serving as a temporary set of instructions for cellular machinery, so it doesn't stick around long. But for the purposes of medicine, it needs to be optimized so that it's both durable enough to provide an efficacious dose, but still transient enough to minimize potential side effects. The potential combinations are mind boggling. For example, there are 10^623 different ways to combine nucleotides in mRNA to encode for the same protein as the company's COVID vaccine, Davis said. To put that in perspective, 'there's only 10^80 particles in the universe,' he said. 'The numbers just go crazy.' Conventional computers, even supercomputers using the best AI algorithms, struggle with this sort of problem, he said. For one, because mRNA is so fragile, there aren't a lot of known structures that an AI program could be trained on. And when it comes to optimization of structures, the numbers are so large that it's difficult to scale, forcing chemists to rely on rules of thumb and oversimplifying the data to try and find solutions. Moderna has found one solution: quantum computing. It recently partnered with IBM to use its quantum hardware to optimize mRNA structures. Quantum computers are uniquely suited to solving large scale optimization problems like this, because they can search and compute potential solutions in parallel. By contrast conventional computers have to calculate everything in sequence, which goes ever slower the bigger the problem gets. Using IBM's quantum computers, Moderna was able to predict a 60-nucleotide sequence of mRNA. The previous record was only eight. While that's still a long way from the sequence lengths, comprising thousands of nucleotides, that biotech companies will need, it shows a potential new way to find new mRNA therapies. More importantly, it could lead to breakthroughs that might have never been discovered with conventional approaches. With quantum algorithms, Davis said, 'you get into the space of possibilities in a different way than some of the classical approaches.' BIOTECH AND PHARMA CAR-T cell therapy has been a life-saving treatment for patients with cancers like leukemia or lymphoma, with many going into remission. But the therapy so far has been less successful on solid tumors, which comprise most cancers. Dispatch Bio aims to change that: The three year-old company emerged from stealth today with $216 million in funding led by Midas Lister Bob Nelsen's ARCH Venture Partners and the Parker Institute for Cancer Immunotherapy. One reason it's challenging to treat solid cancers with CAR-T therapy is that it's more difficult for the cells to identify their targets, Dispatch Bio CEO Sabah Oney told Forbes . To get around this, Dispatch has developed a viral vector that targets cancer cells and then 'tags' them with a protein that the T-cells can use to attack the cancer. The virus uses the cancer cells' own replication system to make copies of itself, making it difficult for the cancer to develop a resistance to it. Because this mechanism is different in healthy cells, the risk is lower that the therapy would attack them. So far, the Philadelphia-based company has tested its therapy in both human cells in the lab and in animals, Oney said. It plans to start clinical trials in 2026, but is still working out what indication it will go after first. 'Ultimately, we have plans to be able to scale this approach so we can get to millions and millions of patients because that's the broad potential of this platform,' he said. 'We can do lung cancer, breast cancer, colon cancer with the same drug.' Plus : AstraZeneca plans to invest $50 billion in U.S. drug development and manufacturing by 2030 as pharma companies look for ways to deal with Trump's tariffs. DIGITAL HEALTH AND AI Mental healthcare startup Slingshot AI launched an AI-powered chatbot to provide support for those dealing with mental health issues. It simultaneously raised $53 million in venture funding led by Forerunner Ventures and Radical Ventures, bringing total funding to $93 million, at an undisclosed valuation. The chatbot, called Ash, has been beta tested with more than 50,000 patients. Plus : Aidoc, which has developed FDA-cleared algorithms for use by radiologists, raised $150 million led by General Catalyst and Square Peg at an undisclosed valuation. PUBLIC HEALTH AND HOSPITALS The FDA has named George Tidmarsh, a pediatric oncologist and pharma company veteran, as its top drug regulator, director of its Center for Drug Evaluation and Research. He will replace Jacqueline Corrigan-Curay, who has been serving in the role in an acting capacity after the departure of former director Patrizia Cavazzoni in January. Tidmarsh has led teams that have developed seven FDA-approved drugs and has served as CEO of several pharmaceutical companies in addition to being an adjunct professor at the Stanford School of Medicine. He takes over as the FDA has faced substantial upheaval under HHS Secretary Robert F. Kennedy Jr. WHAT WE'RE READING How a push for increased organ donation led to people enduring rushed or premature attempts to remove their organs. Wellness startup Truemed, cofounded by RFK Jr. aide Calley Means, helps people buy Peloton bikes and $9,000 saunas with tax-free funds set aside for healthcare. Bankrupt hospital system Steward Health sued its former CEO claiming he conducted insider transactions that drained its assets and led to its collapse. AI companies, including OpenAI, Grok and others have stopped warning users that their chatbots aren't doctors. Life sciences investment firm Omega Funds has raised $647 million for its eighth fund. Researchers figured out a way to deliver a vaccine using dental floss, which has so far been successfully tested on mice. Former Citigroup chair Sandy Weill gave $100 million to harness AI for a West Coast cancer hub. MORE FROM FORBES Forbes Vibe Coding Turned This Swedish AI Unicorn Into The Fastest Growing Software Startup Ever By Iain Martin Forbes Why JPMorgan Is Hitting Fintechs With Stunning New Fees For Data Access By Jeff Kauflin Forbes Go Back To The Office, But Bring Your Own Snacks. Blame Congress. By Kelly Phillips Erb
Yahoo
an hour ago
- Yahoo
Generational Group Posts Historic H1 2025 Performance
DALLAS, July 23, 2025--(BUSINESS WIRE)--Generational Group, a leading investment banking firm for privately held businesses, is proud to announce a record-setting start to 2025, having successfully closed 92 transactions in the first half of the year. The landmark start saw M&A revenue climb 20% and enterprise value transacted soar over 30%, reflecting the market's resilient buoyancy. This milestone underscores the firm's unwavering commitment to delivering outstanding results and signals a highly anticipated surge in M&A activity for the remainder of the year. Despite economic uncertainty following the first quarter, M&A activity has remained strong and continues to gain steam. Buyers and sellers alike are navigating the market thoughtfully, fostering consistent deal flow across a wide range of industries. Several macroeconomic factors are fueling the current uptick in transactions: increasing stability under the new administration, anticipated regulatory changes in banking, improving economic indicators, and targeted executive actions—all contributing to renewed buyer confidence and an acceleration in deal-making. "The momentum we saw in Q1 stalled in Q2 as tariff uncertainties delayed transactions," said Brenen Hofstadter, Chief M&A Officer at Generational Group. "Fortunately, while many deals were delayed, most have since closed, and M&A activity has regained steam due to several factors. The tariff smoke has cleared, Business Cycle Indicators are bullish, the inflation rate is declining, and I expect the FED to cut rates at its next meeting. Zooming out, we're fully in the midst of the M&A Super Cycle we began forecasting a long time ago." Ryan Binkley, President and CEO of Generational Group, added, "Our record-breaking first half reflects both the trust our clients place in us and the relentless dedication of our team. With strong buyer interest and favorable conditions, we're seeing extraordinary opportunities for business owners considering a full or partial sale. We're encouraged by the market acceleration and grateful for the opportunity to help entrepreneurs realize their goals and dreams." The firm's performance in 2025 also marks a broader milestone: Generational has now surpassed 1,700 closed transactions, further solidifying its reputation as a top-tier advisor in the middle market. In 2024, the firm was named Investment Banking Firm of the Year by The M&A Advisor and also received top honors from the Global M&A Network. Generational continues to lead the industry, ranking first or second in completed North American transactions across all deal categories from $25 million to $1 billion in 2022, 2023, and 2024, according to annual league tables published by LSEG (formerly Refinitiv). About Generational Group Generational Group, headquartered in Dallas, TX, is a leading, award winning full-service M&A advisory firm. Generational has over 300 professionals across 16 offices in North America. The firm empowers business owners to unlock the full value of their companies through a comprehensive suite of services—including strategic growth consulting, exit planning education, business valuation, value enhancement strategies, M&A advisory, digital solutions, and wealth management. Celebrating its 20th year, Generational has successfully closed over 1,700 transactions and has ranked #1 or #2 in all LSEG league tables for deals valued between $25 million and $1 billion in 2022, 2023, and 2024. The firm was named 2024 USA Investment Banking Firm of the Year by the Global M&A Network and recognized as Investment Banking Firm of the Year by The M&A Advisor in both 2024 and 2022. View source version on Contacts Media Contact:Catherine Binkley469-828-2798cbinkley@ Sign in to access your portfolio
